×
About 225,408 results

ALLMedicine™ Heart Failure Center

Research & Reviews  101,935 results

Commentary on: Renin-angiotensin system overactivation in perivascular adipose tissue c...
https://doi.org/10.1042/CS20210017
Clinical Science (London, England : 1979); Ferrario CM

Mar 2nd, 2021 - We comment on the publication of a paper in which Brazilian investigators evaluate the anticontractile response of perivascular adipose tissue (PVAT) in experimental heart failure (HF) induced in rats by occlusion of a coronary artery.

Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Depende...
https://doi.org/10.1161/CIRCULATIONAHA.120.047904
Circulation Querdel E, Reinsch M et. al.

Mar 2nd, 2021 - Background: Human engineered heart tissue (EHT) transplantation represents a potential regenerative strategy for heart failure patients and has been successful in preclinical models. Clinical application requires upscaling, adaptation to good manu...

Machine learning based on biomarker profiles identifies distinct subgroups of heart fai...
https://doi.org/10.1002/ejhf.2144
European Journal of Heart Failure; Woolley RJ, Ceelen D et. al.

Mar 2nd, 2021 - The lack of effective therapies for patients with heart failure with preserved ejection fraction (HFpEF) is often ascribed to the heterogeneity of patients with HFpEF. We aimed to identify distinct pathophysiologic clusters of HFpEF based on circu...

Innovations in Cardiac Implantable Electronic Devices.
https://doi.org/10.1007/s10557-021-07163-5 10.1046/j.1460-9592.2003.00162.x 10.1111/j.1540-8159.2011.03150.x 10.1016/j.hrthm.2011.12.014 10.1016/j.jacc.2009.06.006 10.1016/j.ijcard.2015.03.053 10.1093/eurheartj/eht511 10.1161/CIRCULATIONAHA.113.006987 10.1038/s41569-019-0224-z 10.1016/j.hrthm.2019.05.011 10.1016/j.hrthm.2017.01.035 10.1016/j.hrthm.2017.07.004 10.1016/j.ahj.2019.04.002 10.1016/j.ccep.2017.11.003 10.1016/j.hrthm.2018.05.004 10.1016/j.jacep.2019.10.017 10.1056/NEJMoa1511643 10.1016/j.hrthm.2017.05.017 10.1016/j.hrthm.2018.08.005 10.1161/01.CIR.72.5.1037 10.1093/europace/euz230 10.1016/j.jacbts.2018.07.009 10.1016/j.hrthm.2019.01.010 10.1111/pace.13750 10.1016/j.jacep.2017.04.002 10.1111/j.1540-8159.2004.00549.x 10.1016/j.amjcard.2010.01.004 10.1161/01.CIR.101.8.869 10.1053/pcad.2002.130388 10.15420/aer.2018.6.2 10.1161/01.CIR.39.1.13 10.1157/13089742 10.1007/s10840-011-9565-1 10.1093/europace/eun089 10.1093/europace/eus313 10.1016/j.jacc.2018.06.017 10.1016/j.jacc.2018.02.048 10.1016/j.jacc.2019.04.026 10.1016/j.jacc.2006.01.056 10.1093/europace/euu011 10.1161/JAHA.118.010972 10.1002/ehf2.12315 10.1093/eurheartj/ehm262 10.1016/j.cjca.2017.09.013 10.1016/j.hroo.2020.03.002 10.1161/CIRCEP.115.003344 10.1016/j.jacc.2019.10.039 10.1016/j.hrthm.2019.09.006 10.1016/j.hrcr.2019.01.006 10.1016/j.hrthm.2019.04.043 10.1093/europace/euy252 10.1016/j.hrthm.2019.05.014 10.1093/europace/euz188 10.1161/CIRCRESAHA.118.313571 10.1136/openhrt-2014-000198 10.1016/j.jacc.2015.11.026 10.1016/j.jacc.2016.08.044 10.1016/j.hlc.2018.09.011 10.1016/j.jacep.2017.07.017 10.1016/j.hrthm.2015.09.010 10.1016/j.hrthm.2018.09.029 10.1016/j.ahj.2019.05.002 10.1056/NEJMoa1915932 10.1161/CIRCULATIONAHA.120.048728 10.1016/j.jacep.2016.12.026 10.1016/j.jacep.2018.11.003 10.15420/cfr.2016:25:2 10.1056/NEJMoa050496 10.2217/fca-2019-0044 10.1016/j.jacc.2008.01.036 10.1002/ejhf.1349 10.1161/CIRCHEARTFAILURE.119.006512 10.1093/eurheartj/ehn020 10.1016/j.ahj.2010.10.025 10.1002/ejhf.1374 10.1253/circj.CJ-10-1268 10.1093/eurheartj/ehs305 10.1016/j.jelectrocard.2014.08.011 10.1016/j.ijcard.2018.10.086 10.7205/MILMED-D-17-00017 10.1016/S0140-6736(11)60101-3 10.1016/j.jchf.2015.12.015 10.1002/ejhf.592 10.1007/s12471-019-01342-8 10.1161/CIRCULATIONAHA.111.043042 10.1002/ejhf.626 10.1016/j.jacc.2007.10.061 10.1016/j.jacc.2017.05.052 10.1161/01.CIR.97.21.2154 10.1161/CIRCULATIONAHA.105.543173 10.21037/jtd.2018.03.59 10.1016/S0140-6736(16)30961-8 10.1016/j.amjcard.2018.02.022 10.1161/CIRCULATIONAHA.106.683482 10.1093/eurjhf/hfq183 10.1016/j.jacc.2007.01.084 10.1002/ejhf.1312
Cardiovascular Drugs and Therapy; Khan K, Kim JA et. al.

Mar 2nd, 2021 - Cardiac implantable electronic devices (CIEDs) are essential for the management of a variety of cardiac conditions, including tachyarrhythmias, bradyarrhythmias, and medically refractory heart failure (HF). Recent advancements in CIED technology h...

see more →

Guidelines  317 results

Coffee lovers, rejoice! Drinking more coffee associated with decreased heart failure risk
https://newsroom.heart.org/news/coffee-lovers-rejoice-drinking-more-coffee-associated-with-decreased-heart-failure-risk
American Heart Association

Feb 8th, 2021 - DALLAS, Feb. 9, 2021 — Dietary information from three large, well-known heart disease studies suggests drinking one or more cups of caffeinated coffee may reduce heart failure risk, according to research published today in Circulation: Heart Failu...

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart...
https://doi.org/10.1016/j.jacc.2020.11.022
Journal of the American College of Cardiology; , Maddox TM et. al.

Jan 15th, 2021 - 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set...

2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A...
https://doi.org/10.1016/j.jacc.2020.07.023
Journal of the American College of Cardiology; Heidenreich PA, Fonarow GC et. al.

Nov 6th, 2020 - 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.|2020|Heidenreich PA,Fonarow GC,Breathett K,Jurgens ...

Integrated electrophysiology care for patients with heart failure: An envisioned future.
https://doi.org/10.1016/j.hrthm.2020.10.008
Heart Rhythm; Mason PK, Desai A et. al.

Oct 16th, 2020 - Integrated electrophysiology care for patients with heart failure: An envisioned future.|2020|Mason PK,Desai A,Ajijola OA,Amin AK,Barbhaiya C,|

Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study
https://www.journal-of-cardiology.com/article/S0914-5087(20)30271-9/fulltext
Journal of Cardiology; Kwak S

Aug 25th, 2020 - Patients with heart failure (HF) are more at risk of developing cancer than the general population.

see more →

Drugs  2,773 results see all →

Clinicaltrials.gov  111,343 results

Commentary on: Renin-angiotensin system overactivation in perivascular adipose tissue c...
https://doi.org/10.1042/CS20210017
Clinical Science (London, England : 1979); Ferrario CM

Mar 2nd, 2021 - We comment on the publication of a paper in which Brazilian investigators evaluate the anticontractile response of perivascular adipose tissue (PVAT) in experimental heart failure (HF) induced in rats by occlusion of a coronary artery.

Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Depende...
https://doi.org/10.1161/CIRCULATIONAHA.120.047904
Circulation Querdel E, Reinsch M et. al.

Mar 2nd, 2021 - Background: Human engineered heart tissue (EHT) transplantation represents a potential regenerative strategy for heart failure patients and has been successful in preclinical models. Clinical application requires upscaling, adaptation to good manu...

Machine learning based on biomarker profiles identifies distinct subgroups of heart fai...
https://doi.org/10.1002/ejhf.2144
European Journal of Heart Failure; Woolley RJ, Ceelen D et. al.

Mar 2nd, 2021 - The lack of effective therapies for patients with heart failure with preserved ejection fraction (HFpEF) is often ascribed to the heterogeneity of patients with HFpEF. We aimed to identify distinct pathophysiologic clusters of HFpEF based on circu...

Innovations in Cardiac Implantable Electronic Devices.
https://doi.org/10.1007/s10557-021-07163-5 10.1046/j.1460-9592.2003.00162.x 10.1111/j.1540-8159.2011.03150.x 10.1016/j.hrthm.2011.12.014 10.1016/j.jacc.2009.06.006 10.1016/j.ijcard.2015.03.053 10.1093/eurheartj/eht511 10.1161/CIRCULATIONAHA.113.006987 10.1038/s41569-019-0224-z 10.1016/j.hrthm.2019.05.011 10.1016/j.hrthm.2017.01.035 10.1016/j.hrthm.2017.07.004 10.1016/j.ahj.2019.04.002 10.1016/j.ccep.2017.11.003 10.1016/j.hrthm.2018.05.004 10.1016/j.jacep.2019.10.017 10.1056/NEJMoa1511643 10.1016/j.hrthm.2017.05.017 10.1016/j.hrthm.2018.08.005 10.1161/01.CIR.72.5.1037 10.1093/europace/euz230 10.1016/j.jacbts.2018.07.009 10.1016/j.hrthm.2019.01.010 10.1111/pace.13750 10.1016/j.jacep.2017.04.002 10.1111/j.1540-8159.2004.00549.x 10.1016/j.amjcard.2010.01.004 10.1161/01.CIR.101.8.869 10.1053/pcad.2002.130388 10.15420/aer.2018.6.2 10.1161/01.CIR.39.1.13 10.1157/13089742 10.1007/s10840-011-9565-1 10.1093/europace/eun089 10.1093/europace/eus313 10.1016/j.jacc.2018.06.017 10.1016/j.jacc.2018.02.048 10.1016/j.jacc.2019.04.026 10.1016/j.jacc.2006.01.056 10.1093/europace/euu011 10.1161/JAHA.118.010972 10.1002/ehf2.12315 10.1093/eurheartj/ehm262 10.1016/j.cjca.2017.09.013 10.1016/j.hroo.2020.03.002 10.1161/CIRCEP.115.003344 10.1016/j.jacc.2019.10.039 10.1016/j.hrthm.2019.09.006 10.1016/j.hrcr.2019.01.006 10.1016/j.hrthm.2019.04.043 10.1093/europace/euy252 10.1016/j.hrthm.2019.05.014 10.1093/europace/euz188 10.1161/CIRCRESAHA.118.313571 10.1136/openhrt-2014-000198 10.1016/j.jacc.2015.11.026 10.1016/j.jacc.2016.08.044 10.1016/j.hlc.2018.09.011 10.1016/j.jacep.2017.07.017 10.1016/j.hrthm.2015.09.010 10.1016/j.hrthm.2018.09.029 10.1016/j.ahj.2019.05.002 10.1056/NEJMoa1915932 10.1161/CIRCULATIONAHA.120.048728 10.1016/j.jacep.2016.12.026 10.1016/j.jacep.2018.11.003 10.15420/cfr.2016:25:2 10.1056/NEJMoa050496 10.2217/fca-2019-0044 10.1016/j.jacc.2008.01.036 10.1002/ejhf.1349 10.1161/CIRCHEARTFAILURE.119.006512 10.1093/eurheartj/ehn020 10.1016/j.ahj.2010.10.025 10.1002/ejhf.1374 10.1253/circj.CJ-10-1268 10.1093/eurheartj/ehs305 10.1016/j.jelectrocard.2014.08.011 10.1016/j.ijcard.2018.10.086 10.7205/MILMED-D-17-00017 10.1016/S0140-6736(11)60101-3 10.1016/j.jchf.2015.12.015 10.1002/ejhf.592 10.1007/s12471-019-01342-8 10.1161/CIRCULATIONAHA.111.043042 10.1002/ejhf.626 10.1016/j.jacc.2007.10.061 10.1016/j.jacc.2017.05.052 10.1161/01.CIR.97.21.2154 10.1161/CIRCULATIONAHA.105.543173 10.21037/jtd.2018.03.59 10.1016/S0140-6736(16)30961-8 10.1016/j.amjcard.2018.02.022 10.1161/CIRCULATIONAHA.106.683482 10.1093/eurjhf/hfq183 10.1016/j.jacc.2007.01.084 10.1002/ejhf.1312
Cardiovascular Drugs and Therapy; Khan K, Kim JA et. al.

Mar 2nd, 2021 - Cardiac implantable electronic devices (CIEDs) are essential for the management of a variety of cardiac conditions, including tachyarrhythmias, bradyarrhythmias, and medically refractory heart failure (HF). Recent advancements in CIED technology h...

see more →

News  8,911 results

Most Severe COVID Tied to Four Cardiometabolic Conditions
https://www.medscape.com/viewarticle/946488

Feb 24th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The majority of COVID-19 hospitalizations in the United States are attributable to four preexisting cardiometabolic conditions, a new study sugges...

More From DAPA-HF: Dapagliflozin Quickly Reduces Heart Failure Events
https://www.medscape.com/viewarticle/946297

Feb 22nd, 2021 - Dapagliflozin's benefits in patients with heart failure with reduced ejection fraction appeared quickly after treatment began, and patients who had been hospitalized for heart failure within the prior year got the biggest boost from the drug, acco...

Is Taking Blood Pressure Medications at Night Really Better?
https://www.medscape.com/viewarticle/945200

Feb 21st, 2021 - One of the ways to diagnose high blood pressure is with a 24-hour blood pressure monitor. In healthy people, nocturnal blood pressure dips by about 15% compared with daytime values. Patients who don't have this blood pressure drop at night, often ...

Cardiologist, Antiwar Activist Bernard Lown Dies at 99
https://www.medscape.com/viewarticle/945966

Feb 16th, 2021 - Dr Bernard Lown walks on the bridge renamed in his honor in Lewiston, Maine. BOSTON (AP) — Dr. Bernard Lown, a Massachusetts cardiologist who invented the first reliable heart defibrillator and later co-founded an anti-nuclear war group that was a...

FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF
https://www.medscape.com/viewarticle/945936

Feb 16th, 2021 - The US Food and Drug Administration (FDA) has approved a groundbreaking expanded indication for sacubitril/valsartan (Entresto), making it the first drug in the United States indicated for chronic heart failure (HF) not specifically characterized ...

see more →

Patient Education  129 results see all →